New class of generics could save consumers, insurers billions. FDA is moving carefully.

Jul 13, 2016
The European Union has some 20 "biosimilar" generics on the market; the US has one.
Pre-filled syringes of  the adalimumab biosimilar.  The biosimilar is used in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis and ankylosing spondylitis.
SAM PANTHAKY/AFP/Getty Images

What Brexit may mean for the pharmaceutical industry

Jun 28, 2016
Drug makers are raising concerns Brexit could delay regulatory approval, slow down funding for basic research
British drug makers could face new regulations and road blocks for research as the U.K. prepares to leave the EU. 
Chris Radburn/AFP/Getty Images

Valeant Pharmaceuticals and the dark side of capitalism

Jun 10, 2016
Investors' demands for more profits left patients with the choice to pay up or die.
Howard Schiller, interim CEO of Valeant Pharmaceuticals International, and Nancy Retzlaff, chief commercial officer for Turing Pharmaceuticals, listen during a hearing of the House Oversight and Government Reform Committee on Capitol Hill February 4, 2016 in Washington, DC.
BRENDAN SMIALOWSKI/AFP/Getty Images

Deals aimed at reining in costs of cancer drugs show promise

Jun 6, 2016
Some manufacturers are willing to tie drug price to performance.
Dr. Julie Brahmer (R) and Katie Thornton review PET (Positron Emission Tomography) scans of a patient being treated at the Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Maryland. 
Win McNamee/Getty Images

FTC fights against new strategy for delaying generics

Apr 1, 2016
FTC files case against drug maker for deals cut with two generic firms that extend its monopoly
John Moore/Getty Images

Valeant's story: a cautionary tale

Mar 21, 2016
The company's CEO stepped down on Monday
Howard Schiller, then interim CEO of Valeant Pharmaceuticals International, Inc., listens during a hearing of the House Oversight and Government Reform Committee on Capitol Hill February 4, 2016 in Washington, DC. 
BRENDAN SMIALOWSKI/AFP/Getty Images

FDA takes step to improve generic drug competition

Mar 15, 2016
We'd pay a lot more if it wasn’t for generics, which amount to as much as 85% of what we take.
Joe Raedle/Getty Images

You’ve got questions. We help you answer them.

Support nonprofit, independent journalism that makes you smarter.

Valeant swears off aggressive drug pricing strategy

Mar 15, 2016
Valeant and a handful other firms may ditch a model that's come under fire.
 Valeant and a handful other firms  may ditch a model that's come under fire.
Image via Life Science Association of Manitoba/YouTube

Bad packaging means $3b in drugs will be wasted this year

Mar 1, 2016
A new report suggests drug makers are profiting from the waste.
A new report suggests drug makers are profiting from the waste.
Peter Macdiarmid/Getty Images

Why rare-disease treatments can be big business

Jan 11, 2016
Combined, Shire and Baxalta expect 65 percent of total revenue to come from rare disease treatments.